中山大学药学院(深圳)教授、博士生导师。

国家级青年人才计划入选(2015), 获中国抗癌协会科技二等奖(2023)，上海市市浦东新区 “明珠工程师”，第35届上海市优秀发明选拔赛优秀发明铜奖。

电子邮箱: zhaoyj227@mail.sysu.edu.cn

研究方向：小分子调控蛋白质相互作用、蛋白质靶向降解(PROTAC、分子胶等)和核酸靶向降解，激酶抑制剂，以及原创新药物的临床前成药性优化。

教育背景和工作经历：

  • 2025/9-今中山大学药学院(深圳), 四级教授
  • 2015/3-2025/8 中国科学院上海药物研究所研究员
  • 2009/6-2015/3 美国密西根大学医学院博士后
  • 2005-05--2009-01 新加坡南洋理工大学博士
  • 2003-08--2005-04 新加坡国立大学   博士肄业
  • 1999-09--2003-06 苏州大学   学士

科研项目：

  • 国家自然科学基金委员会，面上项目，82574229, 2026-01至2029-12，在研，主持。
  • 国家自然科学基金委员会，面上项目，82273759, 2023-01至2026-12，在研，主持。
  • 中国科学院上海药物研究所自主部署科研项目, SIMM0320231008, 2023/10-2025/09, 在研，主持。
  • 上海市自然科学基金，面上项目，22ZR1474500，2022-04至2025-03，已结题，主持。
  • 国家自然科学基金委员会，面上项目，82073682，2021-01至2024-12，已结题, 主持。
  • 国家自然科学基金委员会，面上项目，81872724，2019-01至2022-12，已结题，主持。
  • 国家自然科学基金委员会，面上项目，81673295，2017-01至2020-12，已结题，主持。
  • “重大新药创制”科技重大专项, 2018ZX09711002-004-010, 2018-01至2020-12,已结题，主持。
  • 中国科学院战略性先导专项(A类)，项目四、子课题29，XDA12040329，2019-01至2020-09，已结题，主持。
  • 中国科学院战略性先导专项(A类)，项目二、子课题22，XDA12020322，2016-01至2017-12，已结题，主持。
  • 济南市自然科学基金，引进创新团队项目，2021GXRC069，2022-01至2024-12，已结题，主持。
  • 上海市科委化合物高效合成专项，18431907100, 2019/01-2021/12, 已结题, 子课题负责人。

 

代表论文：

  1. Xilin Lyu, Xiancheng Wang, Dongze Lin, Yuhan Lu, Chenxu Wang, Ziqin Yan, Zhiyi Wang, Ying Cheng, Jing Cheng, Xuelian Ren, Yi Su, Shijie Zhang, Yi Chen,* He Huang,* Yujun Zhao* Synthesis of an RBM39 degrader that downregulates CEP192 and induces disorganized spindle structures, Journal of Medicinal Chemistry, 2025, 68, 7807–7826 (IF: 6.8, Year 2024) 最后通讯

  2. Yuhang Lu, Ziqin Yan, Jiaqi Sun, Chenxu Wang, Lan Xu, Xilin Lyu, Xiancheng Wang, Jianfeng Lou, He Huang,* Linghua Meng,* Yujun Zhao*, Selective degradation of TEADs by a PROTAC molecule exhibited robust anticancer efficacy in vitro and in vivo, Journal of Medicinal Chemistry, 2025, 68, 5616-5640. (IF: 6.8, Year 2024) 最后通讯

  3. Hanqing Zhao, Xue Li, Xueyu Yao, Shijie Zhang, Yandan Bao, Weiwei Lu, Minyan Xing, Xudong Wang, Xuan Wang,* Yujun Zhao,* Qian Chu,* and Xiaojie Lu*, Influence of macrocyclization strategies on DNA-encoded cyclic 2 peptide libraries, JACS Au, 2025, 5, 3399−3407. (IF: 8.7, Year 2025) 共同通讯

  4. Zhiyi Wang, Shijie Zhang, Loïca Mélita Irakoze, Yujun Zhao* Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema, European Journal of Medicinal Chemistry, 2025, 117909. (IF: 5.9, Year 2024) 最后通讯

  5. Huan Ling, Lin Li, Liping Duan, Weixue Huang, Jiangnan Zheng, Shijie Zhang, Xinling Li, Xiaorong Qiu, Yang Zhou, Nan Ma, Xiaomei Ren, Jinwei Zhang, Zhen Wang, Yujun Zhao, Ruijun Tian, Zhi-Min Zhang*, and Ke Ding,* O-Cyanobenzaldehydes irreversibly modify both buried and exposed lysine residues in live cells, Journal of American Chemical Society, 2025, 147, 14, 11955–11963 (IF: 14.5, Year 2024)

  6. Xinyuan Wu, Shunyao Li, Ting Liang, Qing Yu, Yiwei Zhang, Jiaxiang Liu, Kaige Li, Zijian Liu, Mengqing Cui, Yongchao Zhao, Xin Han, Rui Jin, Minjia Tan, Xiaohua Chen, Yujun Zhao, Mingyue Zheng, Yi Sun,* Lu Zhou,* and Xiaojie Lu,* Proteome-wide data guides the discovery of lysine-targeting covalent inhibitors using DNA-encoded chemical libraries, Angewandte Chemie International Edition, 2025, DOI: 10.1002/anie.202505581 (IF: 16.6, Year 2024)

  7. MDM2-p53相互作用抑制剂的研究进展和临床现状，张世界，赵玉军*，《药学进展》，2025，49卷，8期，612页。最后通讯

  8. Jianfeng Lou, Qianqian Zhou, Xilin Lyu, Xinyi Cen, Chen Liu, Ziqin Yan, Yan Li, Haotian Tang, Qiupei Liu, Jian Ding, Ye Lu, He Huang,* Hua Xie,* Yujun Zhao,* Discovery of a covalent inhibitor that overcame resistance to Venetoclax in AML cells overexpressing BFL-1, Journal of Medicinal Chemistry, 2024, 67, 10795-10830. (IF: 6.8, Year 2024) 最后通讯

  9. Zhitong Lin, Chen Liu, Ziqin Yan, Jing Cheng,Xiancheng Wang, Feilong Zhou, Xilin Lyu, Shiyan Zhang, Daizhou Zhang, Xiangjing Meng,*Yujun Zhao*, Synthesis and Biological Evaluation of 4-Imidazolidinone–Containing Compounds as Potent Inhibitors of the MDM2/p53 Interaction, European Journal of Medicinal Chemistry, 2024, 116366. (IF: 6.0, Year 2024) 最后通讯

  10. Shaozhao Qin, Lijian Feng, Qingyi Zhao, Ziqin Yan, Xilin Lyu, Kaige Li, Baiyang Mu, Yujie Chen, Weiwei Lu, Chao Wang, Yanrui Suo, Jinfeng Yue, Mengqing Cui, Yingjie Li, Yujun Zhao,* Zhiqiang Duan,* Jidong Zhu,* and Xiaojie Lu,* Discovery and Optimization of WDR5 Inhibitors via Cascade 2 Deoxyribonucleic Acid-Encoded Library Selection Approach, Journal of Medicinal Chemistry, 2024, 67, 1079-1092. (IF: 6.8, Year 2024) 共同通讯

  11. Wenhua Zhu, Cuiting Liu, Kang Xi, Anqi Li, Lian Shen, Yana Li, Miaomiao Jia, Yangbo He, Gang Chen, Chenglong Liu, Yangqiang Chen, Kai Chen, Fan Sun, Daizhou Zhang, Chonggang Duan, Heng Wang, Dongdong Wang, Yujun Zhao,* Xiangjing Meng,* Di Zhu,* Discovery of Novel 1-Phenylpiperidine Urea-Containing Derivatives Inhibiting β-Catenin/BCL9 Interaction and Exerting Antitumor Efficacy Through the Activation of Antigen Presentation of cDC1 Cells, Journal of Medicinal Chemistry, 2024, 67, 12485-12520. (IF: 6.8, Year 2024) 共同通讯

  12. Jing Cheng, Ziqin Yan, Xinzhi Li, Chen Liu, Linjiang Tong, Xilin Lyu, Bingjie Yang, Zheng Chen,* Yujun Zhao*, Structure-based optimization of indoline-containing compounds as second generation inhibitors of NF-κB-inducing kinase (NIK). Journal of Molecular Structure, 2024, 136755. (IF: 4.0, Year 2024)最后通讯

  13. Bo Hou, Jiayi Ye, Lujia Huang, Wenhao Cheng, Fangmin Chen, Huiling Zhou, Jiaxing Pan, Jing Gao, Yi Lai, Yujun Zhao, Wei Huang, Haijun Yu, Zhiai Xu* Tumor-specific delivery of clickable inhibitor for PD-L1 degradation and mitigating resistance of radioimmunotherapy, Science Advances, 2024, 10, eadq3940 (IF: 11.7, Year 2024)

  14. Jing Cheng, Ziqin Yan, Kailong Jiang, Chen Liu, Dehua Xu, Xilin Lyu, Xiaobei Hu, Shiyan Zhang, Yubo Zhou,* Jia Li,* Yujun Zhao*, Discovery of JN122, a Spiroindoline-containing Molecule, that Inhibits MDM2/p53 Protein-protein Interaction and Exerts Robust in vivo Antitumor Efficacy. Journal of Medicinal Chemistry, 2023, 66, 16991-17025. (IF: 7.3, Year 2023) 最后通讯

  15. Ziqin Yan, Xilin Lyu, Dongze Lin, Gaoxing Wu, Yang Gong, Xuelian Ren, Jian Xiao, Jianfeng Lou, He Huang, Yi Chen*, Yujun Zhao*, Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines, European Journal of Medicinal Chemistry, 2023, 115381. (IF: 6.7, Year 2023) 最后通讯

  16. Ying Cheng, Xilin Lyu, Chen Liu, Xiancheng Wang, Jing Cheng, Daizhou Zhang,Xiangjing Meng,* Yujun Zhao*, Synthesis and biological evaluation of sclareolide-indole conjugates and their derivatives. Molecules, 2023, 28, 1737. (IF: 4.92, Year 2022) 最后通讯

  17. Mengnisa Seydimemet, Yixuan Yang, Yuhan Lv, Jiaxiang Liu, Ziqin Yan, Yujun Zhao*, Xuan Wang*, Xiaojie Lu*, Design, construction, and screening of diversified pyrimidine-focused DNA-encoded libraries, ACS Med. Chem. Lett. 2023, 14, 1073−1078. (IF: 4.2, Year 2022) 共同通讯

  18. Shiyan Zhang, Ziqin Yan, Yafang Li, Yang Gong, Xilin Lyu, Jianfeng Lou, Daizhou Zhang, Xiangjing Meng*, Yujun Zhao*, Structure-based discovery of MDM2/4 dual inhibitors that exert antitumor activities against MDM4 -overexpressing cancer cells, Journal of Medicinal Chemistry, 2022, 65, 6207-6230. (IF: 8.03, Year 2022) 最后通讯

  19. Xuexin Feng, Ziqin Yan, Feilong Zhou, Jianfeng Lou, Xilin Lyu, Xuelian Ren, Ziyu Zeng, Chenglong Liu, Shiyan Zhang, Di Zhu, He Huang, Jinming Yang*, Yujun Zhao*, Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells, European Journal of Medicinal Chemistry, 2022, 114327. (IF: 7.08, Year 2022) 最后通讯

  20. Jianfeng Lou, Yuhang Lu, Jing Cheng, Feilong Zhou, Ziqin Yan, Daizhou Zhang,Xiangjing Meng,* Yujun Zhao*, A chemical perspective on the modulation of TEAD transcriptional activities: Recent progress, challenges, and opportunities, European Journal of Medicinal Chemistry, 2022, 114684. (IF: 7.08, Year 2022) 最后通讯

  21. Shiyan Zhang, Jianfeng Lou, Yafang Li, Feilong Zhou, Ziqin Yan, Xilin Lyu, Yujun Zhao*, Recent progress and clinical development of inhibitors that block MDM4/p53 protein-protein interactions, Journal of Medicinal Chemistry, 2021, 64, 10621–10640. (IF: 7.44, Year 2021) 最后通讯

  22. Chenglong Liu, Feilong Zhou, Ziqin Yan, Lian Shen, Xichen Zhang, Fenglian He, Xiaojie Lu, Heng Wang, Ker Yu, Yujun Zhao*, Di Zhu*, Discovery of a novel, potent, and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumor efficacy, British Journal of Pharmacology, 2021, 178, 2651-2670. (IF: 8.73, Year 2021) 共同通讯

  23. Xuan Wang, Jiaxiang Liu, Ziqin Yan, Xiaohong Liu, Sixiu Liu, Yanrui Suo, Weiwei Lu, Jinfeng Yue, Kaixian Chen, Hualiang Jiang, Yujun Zhao*, Mingyue Zheng*, Dongcheng Dai*, Xiaojie Lu*, Diversified strategy for the synthesis of DNA-encoded oxindole libraries, Chemical Science, 2021, 12, 2841-2847. (IF: 9.82, Year 2021) 共同通讯

  24. Jing Cheng, Xuexin Feng, Zhiqiang Li, Feilong Zhou, Jin-Ming Yang, Yujun Zhao*, Pharmacological inhibition of NF-κB-inducing Kinase (NIK) with small molecules for the treatment of human diseases, RSC Medicinal Chemistry, 2021, 12, 552-565. 最后通讯

  25. Xian Zhou, Xuexin Feng, Dachi Wang, Deheng Chen, Gaoxing Wu, Ziqin Yan, Xilin Lyu, Huan Wang, Jin-Ming Yang,* Yujun Zhao*, Synthesis and bioactivity studies of covalent inhibitors derived from (-)-Chaetominine, Journal of Molecular Structure, 2021, 1241, 130694. (IF: 3.19, Year 2021) 最后通讯

  26. Xinzhi Li, Bingchuan Yuan, Min Lu , Yuqin Wang, Na Ding, Chunhong Liu, Ming Gao, Zhicheng Yao, Shiyan Zhang, Yujun Zhao, Liwei Xie, Zheng Chen*,The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression, Nature Communications, 2021, 12, 7213. 

  27. Zhiqiang Li, Xinzhi Li, Ming-Bo Su, Li-Xin Gao, Yu-Bo Zhou, Bingchuan Yuan, Xilin Lyu, Ziqin Yan, Chujiao Hu, Hao Zhang, Cheng Luo, Zheng Chen*, Jia Li*, Yujun Zhao*, Discovery of a potent and selective NF-κB-inducing kinase (NIK) inhibitor that has anti-inflammatory effects in vitro and in vivo, Journal of Medicinal Chemistry, 2020, 63, 4388-4407. (IF: 7.44, Year 2021) 最后通讯

  28. Shiyan Zhang, Chaoying Huang, Xilin Lyu, Peipei Wang, Yi Zang, Zengtao Wang, Huan Wang, Jia Li*, Yujun Zhao*, Discovery of a 2-pyridinyl urea-containing compound YD57 as a potent inhibitor of apoptosis signal -regulating kinase 1 (ASK1), European Journal of Medicinal Chemistry, 2020, 195, 112277. (IF: 6.51, Year 2021) 最后通讯

  29. Xinzhi Li, Yongsen Wu, Yue Song, Na Ding, Min Lu, Linna Jia, Yujun Zhao, Ming Liu, Zheng Chen*, Activation of NF-kB-inducing kinase in islet β-cells causes β-cell failure and diabetes, Molecular Therapy, 2020, 2430-2441. (IF: 11.45, Year 2021)

  30. Deheng Chen, Tian Lu, Ziqin Yan, Wenchao Lu, Feilong Zhou, Xilin Lyu, Biling Xu, Hualiang Jiang, Kaixian Chen, Cheng Luo*, and Yujun Zhao*, Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins, European Journal of Medicinal Chemistry, 2019, 182, 111633. (IF: 6.51, Year 2021) 最后通讯

  31. Erbao Zhao, Feilong Zhou, and Yujun Zhao*, Lewis Acids Promoted 3+2 Cycloaddition of Oxaziridines and Cyclic Allylic Alcohols through Carbonyl Imine Intermediates, Journal of Organic Chemistry, 2019, 84 (7), 4282–4293. (IF: 4.35, Year 2021) 最后通讯

  32. Deheng Chen, Dexiang Guo, Ziqin Yan, Yujun Zhao*, Allenamide as a bioisostere of acrylamide in design and synthesis of targeted covalent inhibitors Med. Chem. Commun. 2018, 9, 244-253. (IF: 2.80, Year 2020) 最后通讯

  33. Feilong Zhou, Erbao Zhao, Ziqin Yan, Deheng Chen, Yujun Zhao*, Synthesis of 3,4-diarylsubstituted hexahydro-1H-indoles, Tetrahedron Letters, 2018, 59, 1871-1874. (IF: 2.41, Year 2021) 最后通讯

  34. Xiaomeng Ren, Xinzhi Li, Linna Jia, Deheng Chen, Hai Hou, Liangyou Rui, Yujun Zhao*, Zheng Chen*, A small-molecule inhibitor of NF-kB-inducing kinase (NIK) protects liver from toxin-induced inflammation, oxidative stress, and injury, FASEB Journal. 2017, 2, 711-718. (IF: 5.19, Year 2021) 共同通讯

独立工作之前的论文 (Post-doc and Ph.D Research)

  1. Longchuan Bai,† Haibin Zhou,† Renqi Xu,†Yujun Zhao,† Krishnapriya Chinnaswamy, Donna McEachern, Jianyong Chen, Chao-Yie Yang, Zhaomin Liu, Mi Wang, Liu Liu, Hui Jiang, Bo Wen, Praveen Kumar, Jennifer L. Meagher, Duxin Sun, Jeanne A. Stuckey, and Shaomeng Wang, A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo, Cancer Cell, 2019, 36, 498–511. (IF: 31.74, 2021) 共同第一

  2. Haibin Zhou,† Longchuan Bai,† Renqi Xu,†Yujun Zhao,† Jianyong Chen, Donna McEachern, Krishnapriya Chinnaswamy, Bo Wen, Lipeng Dai, Praveen Kumar, Chao-Yie Yang, Zhaomin Liu, Mi Wang, Liu Liu, Jennifer L. Meagher, Han Yi, Duxin Sun, Jeanne A. Stuckey, and Shaomeng Wang, Structure-Based Discovery of SD-36 as a Potent, Selective and Efficacious PROTAC Degrader of STAT3 Protein, Journal of Medicinal Chemistry, 2019, 62(24), 11280-11300. (†Equal contributions) (IF: 7.44, Year 2021) 共同第一

  3. Yujun Zhao,† Bing Zhou, † Longchuan Bai, Liu Liu, Chao-Yie Yang, Jennifer L. Meagher, Jeanne A. Stuckey, Donna McEachern, Sally Przybranowski, Mi Wang, Xu Ran, Angelo Aguilar, Yang Hu, Jeff W. Kampf,Xiaoqin Li, Ting Zhao,Siwei Li, Bo Wen, Duxin Sun, and Shaomeng Wang*, Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor, Journal of Medicinal Chemistry, 2018, 61, 6110−6120. (IF: 6.25)第一作者

  4. Yujun Zhao,Longchuan Bai, Liu Liu,Donna McEachern, Jeanne A. Stuckey, Jennifer L. Meagher, Chao-Yie Yang, Xu Ran,Bing Zhou,Yang Hu,Xiaoqin Li,Bo Wen,Ting Zhao,Siwei Li,Duxin Sun, and Shaomeng Wang*, Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H- pyrimido [4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor, Journal of Medicinal Chemistry, 2017, 60 (9), 3887–3901. (IF: 6.25) 第一作者

  5. Bing Zhou, Jiantao Hu, Fuming Xu, Zhuo Chen, Longchuan Bai, Ester Fernandez-Salas, Mei Lin, Liu Liu, Chao-Yie Yang, Yujun Zhao, Donna McEachern, Sally Przybranowski, Bo Wen, Duxin Sun, and Shaomeng Wang*, Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression,Journal of Medicinal Chemistry, 2018 , 61(2), 462-481. (IF: 6.25 ) 

  6. Shaomeng Wang*, Yujun Zhao, Angelo Aguilar, Denzil Bernard, and Chao-Yie Yang, Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges, Cold Spring Harb Perspect Med, 2017, doi: 10.1101/cshperspect.a026245. (IF: 6.00) 

  7. Longchuan Bai, Bing Zhou, Chao-Yie Yang, Jiao Ji, Donna McEachern, Sally Przybranowski, Hui Jiang, Jiantao Hu, Fuming Xu, Yujun Zhao, Liu Liu, Ester Fernandez-Salas, Jing Xu, Yali Dou, Bo Wen, Duxin Sun, Jennifer Meagher, Jeanne Stuckey, Daniel F. Hayes, Shunqiang Li, Matthew J. Ellis, Shaomeng Wang*, Targeted degradation of BET proteins in triple-negative breast cancer, Cancer Research, 2017, 77 (9) 2476-2487. (IF: 9.72)

  8. Xu Ran, Yujun Zhao, Liu Liu, Longchuan Bai, Chao-Yie Yang, Bing Zhou, Jennifer L. Meagher, Krishnapriya Chinnaswamy, Jeanne A. Stuckey, and Shaomeng Wang*, Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors, Journal of Medicinal Chemistry, 2015, 58 (12), 4927-4939. (IF: 6.25) 

  9. C. Gianna Hoffman-Luca, Daniel Ziazadeh, Donna McEachern, Yujun Zhao, Wei Sun, Laurent Debussche and Shaomeng Wang*, Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia in Vitro and in Vivo, Clinical Cancer Research, 2015, 21(11), 2558-2568. (IF: 10.10)

  10. Yujun Zhao, Angelo Aguilar, Denzil Bernard, Shaomeng Wang*, Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment, Journal of Medicinal Chemistry, 2015, 58 (3), 1038-1052. (IF: 6.25) 第一作者

  11. Shaomeng Wang, Wei Sun, Yujun Zhao, Donna McEachern, Isabelle Meaux, Cédric Barrière, Jeanne A. Stuckey, Jennifer L. Meagher, Longchuan Bai, Liu Liu, Cassandra Gianna Hoffman-Luca, Jianfeng Lu, Sanjeev Shangary, Shanghai Yu, Denzil Bernard, Angelo Aguilar, Odette Dos-Santos, Laurent Besret, Stéphane Guerif, Pascal Pannier, Dimitri Gorge-Bernat, and Laurent Debussche, SAR405838: An Optimized MDM2-p53 Interaction Inhibitor in Clinical Development Inducing Complete and Durable Tumor Regression, Cancer Research, 2014, 74, 5855-5865. (IF: 9.72)

  12. Yujun Zhao, Liu Liu, Wei Sun, Jianfeng Lu, Donna McEachern, Xiaoqin Li, Shanghai Yu, Denzil Bernard, Philippe Ochsenbein, Vincent Ferey, Jean-Christophe Carry, Jeffrey R. Deschamps, Duxin Sun, Shaomeng Wang*, Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors, Journal of the American Chemical Society, 2013, 135, 7223–7234. (IF: 14.61) 第一作者

  13. Yujun Zhao,† Shanghai Yu,† Wei Sun,† Liu Liu, Jianfeng Lu, Donna McEachern, Sanjeev Shargary, Denzil Bernard, Xiaoqin Li, Ting Zhao, Peng Zou, Duxin Su, Shaomeng Wang*, A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice, Journal of Medicinal Chemistry, 2013, 56, 5553-5561. (†Equal contributions) (IF: 6.25) 第一作者

  14. Yujun Zhao*, Chao-Yie Yang, Shaomeng Wang*, The Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development, Journal of Medicinal Chemistry, 2013, 56, 7498–7500. (IF: 6.25) 通讯作者

  15. Yujun Zhao, Denzil Bernard, Shaomeng Wang*, Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics, BioDiscovery, 2013, 8: 4, 1-15.第一作者

  16. Bin Li, Yujun Zhao, Yin-Chang Lai, Teck-Peng Loh*, Asymmetric Syntheses of 8-Oxabicyclo[3,2,1]octanes: A Cationic Cascade Cyclization, Angewandte Chemie International Edition, 2012, 51, 8041–8045. (IF: 12.25) 

  17. Denzil Bernard, Yujun Zhao, Shaomeng Wang*, AM-8553: A Novel MDM2 Inhibitor with a Promising Outlook for Potential Clinical Development, Journal of Medicinal Chemistry, 2012, 55, 4934–4935. (IF: 6.25)

  18. Shaomeng Wang, Yujun Zhao, Denzil Bernard, Angelo Aguilar, Sanjeev Kumar Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics Topics in Medicinal Chemistry, 2012, Vol. 8, 57–80. (IF: 3.39 )

  19. Bin Li, Yin-Chang Lai, Yujun Zhao, Yiu-Hang Wang, Zhi-Liang Shen, Teck-Peng Loh*, Synthesis of 3-Oxaterpenoids and Its Application in the Total Synthesis of (±)-Moluccanic Acid Methyl Ester, Angewandte Chemie International Edition, 2012, 51, 10619–10623. (IF: 12.25)

  20. Zheng Chen, Liang Sheng, Hong Shen, Yujun Zhao, Shaomeng Wang, Robert Brink, Liangyou Rui*, Hepatic TRAF2 Regulates Glucose Metabolism Through Enhancing Glucagon Responses, Diabetes, 2012, 61(3), 566–573. (IF: 7.37)

  21. Yujun Zhao, Bin Li, Li-Jun Serena Tan, Zhi-Liang Shen, Teck-Peng Loh*, Enantioselective Cationic Polyene Cyclization vs Enantioselective Intramolecular Carbonyl–Ene Reaction, Journal of the American Chemical Society, 2010, 132, 10242–10244. (IF: 14.61) 第一作者

  22. Yujun Zhao, Serena, Li-Jun Tan, Bin Li,Si-Min Li and Teck-Peng Loh*, Bio-inspired Polyene Cyclization: Aziridinyl Polyene Cyclization Catalyzed by InBr3. ChemicalCommunication (UK), 2009, 3738–3740. (IF: 6.31) 第一作者

  23. Yujun Zhao, Teck-Peng Loh*, Asymmetric Total Synthesis of Antiochic Acid, Organic Letters, 2008, 10, 2143–2145. (IF: 6.09) 第一作者

  24. Yujun Zhao, Teck-Peng Loh*, Bio-inspired Polyene Cyclization: Synthesis of Tetracyclic Terpenoids Promoted by Steroidal Acetal-SnCl4, ChemicalCommunication (UK), 2008, 1434–1436. (IF: 6.31) 第一作者

  25. Yujun Zhao, Teck-Peng Loh*, Practical Synthesis of 1,5-Dimethyl Substituted Conjugated Polyenes from Geranyl Acetate, Tetrahedron, 2008, 64, 4972–4978. (IF: 2.64) 第一作者

  26. Jun-Feng Zhao, Yujun Zhao, Teck-Peng Loh, Indium Tribromide-promoted Arene Terminated Epoxy Olefin Cyclization, ChemicalCommunication (UK), 2008, 1353–1355. (IF: 6.31) 第一作者

  27. Yujun Zhao, Teck-Peng Loh, Bio-inspired Polyene Cyclization Promoted by IntermolecularAcetal-SnCl4or N-Acetal-TiCl4: Investigation of the Mechanism and Identification of the Key Intermediates. Journal of the American Chemical Society, 2008, 130, 10024–10029. (IF: 14.61 ) 第一作者

  28. Yujun Zhao, Shu-Sin Chng, Teck-Peng Loh, Lewis Acid-Promoted Intermolecular Acetal-Initiated Cationic Polyene Cyclizations. Journal of the American Chemical Society, 2007, 129, 492–493. (IF: 14.61) 第一作者

学术专著 (Book Chapters) 

1. Yujun Zhao, Luhang Lu, Ziqin Yan, Xilin Lyu, Shijie Zhang, Chapter 16. Belzutifan: a first-in-class oral HIF-2α inhibitor approved for patients with Von Hippel-Landau (VHL) disease-associated renal cell carcinoma, Book: Drug Discovery Stories, Volume 2, Editors Bin Yu and Peng Zhan, Paperback ISBN: 9780443338854, eBook ISBN: 9780443338861, Elsevier, October 1, 2025.

2. Yujun Zhao, Jianfeng Lou, Yuhang Lu, Feilong Zhou, Ziqin Yan, Chapter 4: The N-sulfonyl carboxamide moiety as a privileged structure in approved drugs, Book: Privileged Scaffolds in Drug Discovery, Academic Press, ISBN: 9780443186110, 2023, 65-80.

3. Shaomeng Wang, Yujun Zhao, Denzil Bernard, Angelo Aguilar, Sanjeev Kumar, Chapter: Protein-Protein Interactions, Book: Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics, Springer-Verlag Berlin Heidelber, 2012, Vol. 8, 57-80, 

 

参编教材

《高等药物化学-药物发现与结构优化的策略》，柳红，陈凯先主编，科学出版社，2025，第二十四章 提高先导化合物的血脑屏障通透性优化策略

代表专利 (Patents of Independent Research):

  1. 赵玉军，楼剑锋，张世界，路宇航，严子琴，一种具有 BFL-1 蛋白结合能力的抑制剂及其制备方法和应用；中国专利申请号: CN2025101510546；申请日期：2025年02月11日；

  2. 赵玉军，蒙凌华，黄河，路宇航，严子琴，吕细林，楼剑锋，孙加奇，徐瓓，王晨旭，任雪莲，一种靶向TEAD的蛋白水解靶向嵌合体及其制备方法和应用；PCT专利申请号：PCT/CN2024/137903；申请日期：2024年12月09日；

  3. 赵玉军，程颖，吕细林，严子琴，周飞龙，草酰二胺衍生物及其用途，中国专利申请号: CN202310218092.X; 申请日期：2023年03月08日；

  4. 赵玉军，李佳，周宇波，程靖，严子琴，吕细林，张世言，周飞龙，刘晨，林芷彤，姜凯龙，徐德华，胡小蓓，具有取代苯基螺[吲哚啉-3,3'-吡咯烷]结构的小分子化合物，PCT专利申请号：WO2024078370；中国专利授权号: ZL202311276504.1；授权日期：2025年09月16日；

  5. 赵玉军，朱棣，周飞龙，严子琴，刘成龙，曾子余，程颖，具有苄氧基芳基醚结构的化合物及其制备方法和用途，PCT专利申请号：WO2023169371；申请日期：2023年03月06日；中国专利申请号: 202210220889.9；申请日期：2022年03月08日。

  6. 赵玉军，李志强，严子琴，李亚芳，吕细林，周飞龙，苯并含氮五元杂环化合物及其合成和应用，中国专利授权号: ZL202210426932.7；申请日期：2022年04月21日；授权日期：2024年08月06日。

  7. 赵玉军，张世言，严子琴，吕细林，程靖，周飞龙，巩洋，具有取代苯基螺[吲哚啉-3,3’-吡咯烷]结构的小分子化合物，PCT专利申请号: WO2022218379；申请日期：2022年04月14；中国专利申请号: 202110407151; 申请日期：2021年04月15日。

  8. 赵玉军，张世言，严子琴，吕细林，周飞龙，具有4-(取代氨甲基)-5-新戊基-N-取代基吡咯烷-2-甲酰胺结构的化合物，中国专利授权号: ZL202111571938.5；申请日期：2021年12月21日；授权日期：2025年05月04日。

  9. 赵玉军，朱棣，周飞龙，严子琴，刘成龙，张希晨，一种具有苄氧基芳环结构的化合物,其制备方法和用途, PCT专利申请号: WO2020244518, 申请日期: 2020年06-02; 中国专利授权号: ZL202010491651.0，申请日期: 2020年06月03日。

  10. 赵玉军，王欢，陈德恒，周飞龙，严子琴，吕细林，具有2H-吲唑结果的小分子化合物及其合成和应用，中国专利授权号: ZL202010135402.8, 申请日期: 2020年03月02日。

  11. 赵玉军、李佳、王增涛、张世言、臧奕、王培培、孙丹丹、张含烟, 2-吡啶取代脲结构小分子化合物及其合成和应用，中国专利授权号: ZL201910716810.X, 申请日期: 2019年08月05日。

  12. 赵玉军、陈德恒、郭德祥、严子琴、周飞龙、耿美玉、丁健、沈爱军、刘红椿、张敏敏，一种BRD4 抑制剂及其制备和应用, 中国专利授权号: ZL201880024931.1, 申请公布日期: 2018年04月13日; PCT专利公布号: WO2018/188660, 公布日期: 2018年10月18日。

  13. 赵玉军，李志强，严子琴，李佳，周宇波，苏明波，陈政，一种具有2-氨基嘧啶结构的化合物，其制备方法和用途，中国专利授权号: ZL201811381899.0；申请日期: 2018年11月20日；

  14. 赵玉军、郭德祥、严子琴，含有共轭联烯酰胺结构的化合物、其制备方法、药物组合物和用途, 中国专利授权号: ZL201711105956.8, 申请日期: 2017年11月10日;

  15. 赵玉军、陈德恒、严子琴，郭德祥，含有共轭联烯结构的化合物、其药物组合物和用途, 中国专利授权号: ZL201710639753.0, 申请日期: 2017年07月31日。

署名专利 (Co-author Patents):

  1. Shaomeng Wang*, Yujun Zhao, Bing Zhou, Angelo Aguilar, Liu Liu, Longchuan Bai, Donna McEachern, Duxin Sun, Bo Wen, Ruijuan Luo, and Ting Zhao, 9H-Pyrimido[4,5-B]indoles and Related Analogs as BET Bromodomain Inhibitors, 2015.2, PCT Patent Publication No.:WO2015131005 A1; US Patent No.: US9580430B2 (2017-02-28), US10253044B2 (2019-04-09).

  2. Shaomeng Wang*, Xu Ran, Yujun Zhao, Chao-Yie Yang, Liu Liu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Jennifer Lynn Meagher, Duxin Sun, Xiaoqin Li, Bing Zhou, Hacer Karatas, Ruijuan Luo, Arul Chinnaiyan, Irfan A. Asangani, BET Bromodomain Inhibitors and therapeutic Methods Using the same, 2014.10.9, PCT Patent Publication No.: WO2014164596 A1; China Patent No.: CN105377851B (2018-07-20); US Patent No.: US9675697B2 (2017-06-13), US10391175B2 (2019-08-27).

  3. Shaomeng Wang*, Yujun Zhao, Wei Sun, Sanjeev Kumar, Lance Leopold, Laurent Debussche, Cedric Barriere, Jeanchristophe Carry, Kwame Amaning, Spiro-Oxindole MDM2 Antagonists, 2012.5.18, PCT Patent Publication No.:WO 2012/065022 A2; China Patent No.: CN103298818B (2016.6.29); US Patent No.:US9302120B2 (2016-04-05)

  4. Shaomeng Wang*, Shanghai Yu, Wei Sun, Sanjeev Kumar Shangary, DuxinSun, Peng Zou, Donna McEachern, Yujun Zhao, Spiro-Oxindole MDM2 Antagonists, 2011.5.19, PCT Patent Publication No.: WO 2011060049; China Patent No.: CN102712650 B (2015-05-20); US Patent No.: US8518984 B2 (2013.8.27); US8877796B2 (2014-11-04). 

  5. Shaomeng Wang*, Jianyong Chen, Yujun Zhao, Cindy Gomez, Longchuan Bai, Zeneta Nikolovska-Coleska, STAT3 Ligands and Therapeutic Uses Thereof, 2010.7.8, PCT Patent Publication No.: WO 2010077589; US Patent No.: US 2011/0319362; China Patent No.: CN 200980156486; European Patent Publication No.: EP2373658 A4

  6. Teck-Peng Loh*, Yujun Zhao, Cyclization Process of Forming a Multiple Ring Compound. 2007.2, PCT Patent Publication No.: WO 2007097719; US Patent No.: US8227645 B2 (2012.1.4);